

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: WILLIAMS, JILL MARIE

eRA COMMONS USER NAME (credential, e.g., agency login): WILLIAJM

POSITION TITLE: Professor of Psychiatry; Director, Division of Addiction Psychiatry

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Pennsylvania State University, PA	BS	05/1989	Animal Bioscience
UMDNJ-Robert Wood Johnson Medical School, NJ	MD	05/1993	Medicine
Duke University Medical Center, NC	Resident	06/1997	Psychiatry
UMDNJ-Robert Wood Johnson Medical School, NJ	Fellow	06/1999	Addiction Psychiatry

**A. Personal Statement**

I have the expertise, leadership, training, expertise and motivation necessary to successfully carry out the proposed research project. I am a Board-Certified Addictions Psychiatrist and have specialized in tobacco and other addictions in populations with behavioral health comorbidity. I am Professor and Director of the Division of Addiction Psychiatry at the Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry. I also hold faculty appointments with the Rutgers-School of Public Health and the Cancer Institute of New Jersey. I have conducted research in tobacco and other addictions for more than 20 years, focused on: 1. Improving treatment outcomes for tobacco use disorder in those with mental illnesses; 2. Helping behavioral health treatment systems incorporate treatment for tobacco use disorder into their work through systems change; 3. Developing and testing curricula on substance use disorders to educate health professionals. I have conducted both behavioral therapy development projects and medication clinical trials to test innovative approaches for treating tobacco dependence in smokers with serious mental illness. I have developed and evaluated specialized curricula for training behavioral health professionals to treat tobacco as well as curricula on the opioid crisis and use of Medications for Opioid Use Disorder (MOUD) for graduate students in health sciences. My experience developing training curricula for behavioral health professionals and manualized treatments for use in mental health settings make me well-equipped to contribute to the development of the *preaddiction* materials, and solicit feedback from other clinical colleagues about the materials, as part of this proposed project.

Ongoing projects that I would like to highlight include:

NJ DHS - NJ Div. of Mental Health and Addiction Svs.

Williams (PI)

10/1/20 – 9/30/24

Train the Trainer Medication Assisted Treatment Education for Rutgers Students.

NJ DHS - NJ Div. of Mental Health and Addiction Svs.

Williams (PI)

7/1/09 – 6/30/24

Using Peer Counselors to Address Tobacco among Mental Health Consumers.

NYC Department of Health and Mental Hygiene

Covell (PI), Role: Co-I

4/1/17- 6/30/24

Tobacco Training Implementation NYC

NJ DOH - NJ Dept. of Mental Health and Addiction Svcs.

Cooperman (PI), Role: Co-I

9/01/16-8/31/24

Opioid Overdose Recovery Network

## **B. Positions and Honors**

### **Positions and Employment**

2019-2022 Vice Chair Research, Rutgers-RWJMS  
2012- Professor of Psychiatry with Tenure, Rutgers-RWJMS  
2008-2012 Associate Professor of Psychiatry with Tenure, UMDNJ-RWJMS  
2007- Director of the Division of Addiction Psychiatry, Rutgers-RWJMS (Formerly UMDNJ)  
2006-2008 Residency Program Director, Addiction Psychiatry Residency Program, UMDNJ-RWJMS  
2005-2012 Associate Professor of Psychiatry, UMDNJ- Robert Wood Johnson Medical School  
2004- Joint Appointment, Rutgers-School of Public Health (Formerly UMDNJ)  
2003- Visiting Professor, Rutgers Center for Addiction Studies  
2002- Member of the Cancer Institute of New Jersey  
2001-2010 Research Psychiatrist, Tobacco Dependence Program. UMDNJ- School of Public Health  
1998-2001 Medical Director, CORE Day Program & Residential Treat Program. VA NJ Health Care System.  
1997-2005 Assistant Professor of Psychiatry, UMDNJ- Robert Wood Johnson Medical School  
1996-1997 Executive Chief Resident, Department of Psychiatry, Duke University Medical Center

### **Other Experience and Professional Memberships**

2019-2022 Associate Editor, British Journal of Psychiatry Open  
2019- 2022 Chair, American Psychiatric Association, Council on Addiction Psychiatry  
2015- American Psychiatric Association, Council on Addiction Psychiatry  
2014-2018 Associate Editor. Journal of Dual Diagnosis.  
2013-2016 Chairperson, NJ Breathes Tobacco Coalition  
2012 Society for Research on Nicotine and Tobacco (SRNT), Program Committee  
2011-2012 NIH Peer Review Committee, RPIA (Risk, Prevention and Intervention for Addictions Study Section ad hoc reviewer  
2005- Association for the Treatment of Tobacco Use and Dependency (ATTUD)  
2005-2007 Alcohol Medical Scholars Program  
2004-2019 CME Course Director and Lecturer. Treating Tobacco Dependence in Mental Health Settings.  
2002-2003 Robert Wood Johnson Foundation, Consultant and Co-Organizer for National Initiative Advisory Panel: Addressing Tobacco amongst Individuals with Mental Illness or Addiction.  
2000-2021 Society for Research on Nicotine and Tobacco (SRNT)

### **Honors**

2020 Distinguished Fellow, American Psychiatric Association  
2015 Remarkable Achievement Award, NJ Psychiatric Association  
2009 Silver Award to CHOICES Program (Williams PI and Co-Founder), American Psychiatric Association Institute of Psychiatric Services  
2004 Future Leaders in Psychiatry  
2004 American Psychiatric Association's Research Colloquium for Junior Investigators  
2000-2001 APIRE/ Janssen Pharmaceutical Public Policy Leadership Program Fellow  
1999 American Psychiatric Association's Research Colloquium for Junior Investigators  
1997 George Ginsberg- American Association of Directors of Psychiatric Residency Training (AADPRT) Charter Fellowship.  
1995-1996 N.C. Governor's Institute for Alcohol and Substance Abuse Public Policy Research Scholar.  
1985 N.J. Garden State Distinguished Scholar

### C. Contributions to Science

1. I have been involved in many clinical trials and other treatment studies of substance use disorders. These have included studies of nicotine dependence and smoking behavior, clinical trials for smoking cessation in individuals with mental illness or other addictions, and enhancing outcomes for a variety of addictive disorders through treatment development. We have conducted medications studies of high dose nicotine replacement and varenicline as well as been a successful site for multisite clinical trials, sponsored by NIDA and other groups. I have also collaborated on studies of behavioral therapy development.
  - a. **Williams JM**, Steinberg ML, Zimmermann MH, Gandhi KK, Stipelman B, Budsock PD, Ziedonis DM. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. *J Subst Abuse Treat.* 2010 Jun;38(4):384-93. doi: 10.1016/j.jsat.2010.03.006. PubMed PMID: 20363089; PubMed Central PMCID: PMC2859987.
  - b. **Williams JM**, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C and George TP. A Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients with Schizophrenia or Schizoaffective Disorder. *J Clin Psychiatry.* 2012 May;73(5):654-60. doi: 10.4088/JCP.11m07522. PubMed PMID: 22697191.
  - c. Cooperman NA, Rizvi SL., Hughes, CD, **Williams, JM**. Field test of a dialectical behavior therapy skills training-based intervention for smoking cessation and opioid relapse prevention in methadone treatment. *Nicotine Tob Res.* 2018 Aug 14;20(9):1152-1156. doi: 10.1093/ntr/ntx189. PubMed PMID: 29059389; PubMed Central PMCID: PMC6093329.
  - d. Cooperman NA, Lu, S. Richter KP, Bernstein SL, **Williams JM**. Pilot study of a tailored smoking cessation intervention for individuals in treatment for opioid dependence. *Nicotine Tob Res.* 2018 Aug 14;20(9):1152-1156. doi: 10.1093/ntr/ntx189. PubMed PMID: 29059389; PubMed Central PMCID: PMC6093329.
  
2. Early work to examine nicotine intake, nicotine metabolism and cigarette puffing topography led to a successful grant in this area that yielded many publications. Findings from this work: 1. Confirmed higher nicotine intake in schizophrenia compared to control smokers without mental illness. This study also identified the mechanism by which higher nicotine intake per cigarette occurs (shorter Interpuff interval). 2A secondary data analysis revealed that commonly used antiepileptic and antimanic drugs carbamazepine, (CBZ) and oxcarbazepine (OCB) induce the metabolism of nicotine at CYP2A6, which had never been previously reported. Nicotine metabolism also appears to be altered in bipolar disorder but not in schizophrenia although the mechanism is unknown and could be due to the effects of medication. We were also able to demonstrate in a human laboratory study that nicotine intake and nicotine boost is greater in schizophrenia even when smoking a single cigarette.
  - a. **Williams JM**, Gandhi KK, Lu SE, Kumar S, Shen J, Foulds J, Kipen H and Benowitz NL. Higher Nicotine Levels in Schizophrenia Compared to Controls after Smoking a Single Cigarette. *Nicotine Tob Res.* 2010 Aug;12(8):855-9. doi: 10.1093/ntr/ntq102. PubMed PMID: 20584771; PubMed Central PMCID: PMC2910875.
  - b. **Williams JM**, Gandhi KK and Benowitz NL. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. *Cancer Epidemiol Biomarkers Prev.* 2010 Oct;19(10):2582-9. doi: 10.1158/1055-9965.EPI-10-0384. PubMed PMID: 20719908; PubMed Central PMCID: PMC2952059.
  - c. **Williams JM**, Gandhi KK, Lu SE, Kumar S, Steinberg ML, Cottler B and Benowitz NL. Shorter Interpuff Interval is Associated with Higher Nicotine Intake in Smokers with Schizophrenia. *Drug Alcohol Depend.* 2011 Nov 1;118(2-3):313-9. doi: 10.1016/j.drugalcdep.2011.04.009. PubMed PMID: 21596491; PubMed Central PMCID: PMC3655704.
  - d. **Williams JM**, Gandhi KK, Lu SE, Steinberg ML and Benowitz NL. Nicotine Intake and Smoking Topography in Smokers with Bipolar Disorder. *Bipolar Disord.* 2012 Sep;14(6):618-27. doi: 10.1111/j.1399-5618.2012.01047.x. PubMed PMID: 22938167; PubMed Central PMCID: PMC3641517.
  
3. My more recent work has been in developing trainings for treating tobacco and other addictions as well as implementing systems changes and tobacco free policy in behavioral health treating settings. I have also done considerable work in curriculum development for addictions. A recent grant was to develop and

evaluate online training modules for psychiatric residents to teach them basics in tobacco assessment and treatment. I also have developed initiatives to train graduate students in health sciences and the lay public in the need for Medications for Opioid Use Disorder (MOUD). I hold leadership positions in Addictions (Chair, APA Council on Addictions) and am an AAAP Certified Trainer for Buprenorphine. My work has included epidemiological studies of disparities in tobacco use and policy papers on the need for smokers with mental illness to be a designated disparity group.

- a. **Williams JM**, Poulsen R, Chaguturu V, Tobia A and Palmeri B. Evaluation of an Online Residency Training in Tobacco Use Disorder. *Am J Addict*. 2019 Jul;28(4):277-284. doi: 10.1111/ajad.12885. PubMed PMID: 30993797
- b. **Williams JM**, Steinberg ML, Wang H, Chaguturu V, Poulsen R, Tobia A, Palmeri B. Practice Change after Training Psychiatry Residents in Tobacco Use Disorder. *Psychiatr Serv*. 2020 Feb 1;71(2):209-212. doi: 10.1176/appi.ps.201900272. PubMed PMID: 31690223; PubMed Central PMCID: PMC7261518.
- c. **Williams JM**, Syed MA, Adesanya A, Gardner G, Chaguturu V and Coppola KM. Educating the Community about the Opioid Epidemic and Medications for Opioid Use Disorder. *J Addict* 2022 Sep;31(5):433-440. PMID:35411688
- d. Covell NH, Foster F, Lipton N, Kingman E, Aquila S and **Williams JM**. Using a Self- Evaluation Tool for Behavioral Health Programs to Support Implementing Treatment for Tobacco Use Disorder. *Community Mental Health Journal*. 2022 May; 58(4):812-820. PMID: 34518927

**Complete List of Published Work in MyBibliography:**

<http://www.ncbi.nlm.nih.gov/sites/myncbi/16QSvwwg6htMkn/bibliography/48072125/public/?sort=date&direction=descending>